d-alpha tocopherol has been researched along with Influenza, Human in 73 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.74) | 18.2507 |
| 2000's | 4 (5.48) | 29.6817 |
| 2010's | 60 (82.19) | 24.3611 |
| 2020's | 7 (9.59) | 2.80 |
| Authors | Studies |
|---|---|
| Buddy Creech, C; Chen, WH; Cross, K; Dickey, M; Goepfert, PA; Logan, HL; Neuzil, KM; Ortiz, JR; Overton, ET; Parker, S; Spearman, PW; Wegel, A | 1 |
| Abdoli, A; Abdollahpour-Alitappeh, M; Eshraghi, Y; Karimi, P; Mahdavi, M; Taghizadeh, M; Vahdani, Y | 1 |
| Feinstein, L; Fessler, MB; London, SJ; Mendy, A; Molsberry, SA; Salo, PM; Thorne, PS; Wilkerson, J; Zeldin, DC | 1 |
| Gao, T; Ma, S; Mai, Y; Yang, J; Yu, N; Yu, R | 1 |
| Amiji, MM; Bertholet, S; Friedrich, K; Henson, D; Kanitkar, AP; Lodaya, RN; Mallett, CP; Nuti, S; O'Hagan, DT; Yamagata, R | 1 |
| Endo, M; Fukuda, T; Hayashida, K; Ibaragi, K; Kino, Y; Naruse, T; Tanabe, T; Tanishima, M; Ueda, K | 1 |
| Andrews, N; Gringras, P; Miller, E; Quinnell, T; Shneerson, J; Stowe, J; Zaiwalla, Z | 1 |
| Barbeau, DM; Bauchau, V; Cohet, C; Dos Santos, G; Seifert, HA; Shinde, V | 1 |
| Borggren, M; Christensen, D; Fomsgaard, A; Karlsson, I; Nielsen, J; Williams, J | 1 |
| Chu, L; Collins, H; Drame, M; Frenette, L; Friel, D; Innis, BL; Madan, A; Schuind, A; Sheldon, E; Vaughn, DW | 1 |
| Del Giudice, G; Didierlaurent, AM; Rappuoli, R | 1 |
| Harandi, AM | 1 |
| Creech, CB; Edwards, KM; Gelber, CE; Goll, JB; Hoek, KL; Howard, LM; Jensen, TL; Joyce, S; Levy, SE; Link, AJ; Prasad, N | 1 |
| Dwyer, DE; Hauser, MI; Muscatello, DJ; Soh, ACY; Turner, RM | 1 |
| Ledgerwood, JE | 1 |
| Beran, J; Caplanusi, A; Claeys, C; Devaster, JM; Durand, C; Duval, X; El Idrissi, M; Esen, M; Falsey, AR; Feldman, G; Frey, SE; Galtier, F; Hwang, SJ; Innis, BL; Kovac, M; Kremsner, P; Launay, O; Leroux-Roels, G; McElhaney, JE; McNeil, S; Nowakowski, A; Oostvogels, L; Richardus, JH; Ruiz-Palacios, GM; Trofa, A; van Essen, GA | 1 |
| Bambure, V; Gillard, P; Hanon, E; Kafeja, F; Moris, P; Roman, F; Van Damme, P | 1 |
| Bruun Laursen, A | 1 |
| Aggarwal, N; Dionne, M; Godeaux, O; Kyle, M; Li, P; Madariaga, M; Vaughn, DW; Yang, WH | 1 |
| De Serres, G; Drolet, JP; Gagnon, R; Landry, M; Ménard, S; Ouakki, M; Rouleau, I; Skowronski, DM; Toth, E | 1 |
| Li, P; Poder, A; Roy-Ghanta, S; Simurka, P; Vaughn, D | 1 |
| Coleman, LA; Meydani, SN; Shay, DK; Sundaram, ME; Vandermause, M | 1 |
| Ahmed, SS; MacDonald, NE; Schur, PH; Steinman, L | 1 |
| Cooper, C; Gipson, E; Haase, D; Halperin, S; Klein, M; Scheifele, D; Walmsley, S; Ward, BJ; Yam, KK | 1 |
| Allwinn, R; Bickel, M; Brodt, HR; Doerr, HW; Herrmann, E; Jung, O; Kroon, FP; Lais, C; Stephan, C; Wieters, I | 1 |
| De Wals, P; Deceuninck, G; Desautels, A; Mignot, E; Montplaisir, J; Ouakki, M; Petit, D; Quinn, MJ | 1 |
| Drame, M; Frenette, L; Godeaux, O; Innis, BL; Izurieta, P; Jeanfreau, R; Kosalaraksa, P; Madariaga, M; Vaughn, DW | 1 |
| Dramé, M; Giet, D; Gillard, P; Heijmans, S; Roman, F; Walravens, K | 1 |
| Boutet, P; Carmona Martinez, A; Devaster, JM; Salamanca de la Cueva, I; Smolenov, I; Vanden Abeele, C | 1 |
| Chu, L; Dramé, M; Frenette, L; Fries, L; Halperin, SA; Jeanfreau, R; Kyle, M; Langley, JM; McNeil, S; Moris, P; Vaughn, DW | 1 |
| Cohet, C; Dewe, W; Drame, M; Fries, LF; Hepburn, A; Innis, BL; Li, P; Seifert, H; Vaughn, DW | 1 |
| Baldó, JM; Díez-Domingo, J; Garcés-Sánchez, M; Garcia-Corbeira, P; Gillard, P; Jubert-Rosich, A; Marès, J; Moris, P; Planelles-Catarino, MV; Teko, M; Ubeda, I; Vanden Abeele, C | 1 |
| Drame, M; Innis, BL; Schuind, A; Segall, N | 1 |
| Dramé, M; Izurieta, P; Kim, WJ; Lee, J; Lee, JS; Schuind, A; Vaughn, DW; Wie, SH | 1 |
| Cox, RJ; Jul-Larsen, Å; Lartey, S; Montomoli, E; Pathirana, RD; Wood, J; Zhou, F | 1 |
| Bambure, V; Berglund, J; Caplanusi, A; Dieussaert, I; Flodmark, CE; Korhonen, T; Lindstrand, A; Richardus, JH; Roy-Ghanta, S; Silfverdal, SA; Vaughn, DW; Vesikari, T | 1 |
| Arístegui, J; Bambure, V; Caplanusi, A; Carmona, A; Dieussaert, I; García-Corbeira, P; Garcia-Sicilia, J; Gillard, P; Merino, JM; Moris, P; Omeñaca, F; Tejedor, JC; Walravens, K | 1 |
| Anderson, EL; Atmar, RL; Bellamy, AR; Berry, AA; Campbell, JD; Creech, CB; Edwards, KM; El Sahly, HM; Frey, SE; Graham, I; Gutierrez, AF; Hill, H; Jackson, LA; Keitel, WA; Kotloff, KL; Noah, DL; Patel, SM; Thomsen, IP | 1 |
| Bédard, F; De Serres, G; Dupré, N; Lacroix, K; Landry, M; Ouakki, M; Rouleau, I; Skowronski, DM; Toth, E | 1 |
| Fukuda, T; Ichikawa, M; Kimachi, K; Kino, Y; Naruse, T; Oda, Y; Tanabe, T; Tochihara, S; Ueda, K | 1 |
| Chen, WH; Creech, CB; Edwards, KM; Hill, H; Jackson, LA; Keitel, WA; Kotloff, KL; Mangal, B; Noah, DL; Patel, SM | 1 |
| Elizabeth Halloran, M; Feldstein, LR; Keitel, WA; Longini, IM; Matrajt, L | 1 |
| Hertz, T; Johnson, C; Karlsson, EA; Krammer, F; Mehle, A; Schultz-Cherry, S | 1 |
| Ferguson, M; Frenette, L; Friel, D; Innis, BL; Kroll, R; Li, P; Madan, A; Schuind, A; Segall, N; Soni, J | 1 |
| Benoit, A; Beran, J; Claeys, C; Devaster, JM; Dewé, W; Durand, C; Duval, X; Esen, M; Falsey, AR; Feldman, G; Galtier, F; Gervais, P; Hwang, SJ; Launay, O; Leroux-Roels, G; McElhaney, JE; McNeil, S; Oostvogels, L; Richardus, JH; Ruiz-Palacios, GM; Trofa, A; van Essen, GA | 1 |
| Galson, JD; Kelly, DF; Trück, J; van der Most, R | 1 |
| Chu, L; Ferguson, M; Friel, D; Innis, BL; Li, P; Madan, A; Rheault, P; Schuind, A; Segall, N; Sheldon, E; Soni, J; Toma, A | 1 |
| Allen, RJ; Andrews, N; Casey, M; Collinson, AC; Eccleston, PE; Faust, SN; Finn, A; Heath, PT; Hoschler, K; John, T; Ladhani, S; Miller, E; Oeser, C; Okike, I; Pollard, AJ; Reiner, A; Sheasby, E; Snape, MD; Waddington, CS; Waight, P; Walker, WT; Wilkins, S | 1 |
| Arístegui, J; Carmona, A; Dieussaert, I; Gillard, P; Merino, JM; Omeñaca, F; Tejedor, JC; Vaman, T | 1 |
| Allen, R; Andrews, N; Casey, M; Collinson, A; Eccleston, P; Faust, S; Finn, A; Heath, P; Hoschler, K; John, T; Ladhani, S; Miller, E; Oeser, C; Okike, I; Pollard, A; Reiner, A; Sheasby, E; Snape, M; Waddington, C; Waight, P; Walker, W; Wilkins, S | 1 |
| Akselsen, PE; Cox, RJ; Jul-Larsen, A; Madhun, AS; Major, D; Mohn, K; Nilsen, M; Nøstbakken, JK; Pedersen, G; Sjursen, H; Smith, I; Svindland, S; Wood, J | 1 |
| Faust, SN; Walker, WT | 1 |
| Andrews, N; Miller, E; Waight, P; Yung, CF | 1 |
| Aristegui, J; Behre, U; Caplanusi, A; Carmona, A; Dieussaert, I; Garcia-Sicilia, J; Gillard, P; Merino, JM; Tejedor, JC; Vaman, T | 1 |
| Allen, R; Andrews, NJ; Casey, M; Chalk, J; Collinson, AC; Faust, SN; Fineman, N; Finn, A; Fletcher, M; Heath, PT; Hoschler, K; John, T; Kerridge, S; Ladhani, S; Michaelis, L; Miller, E; Oeser, C; Okike, I; Pollard, AJ; Reiner, A; Sheasby, L; Snape, MD; Waddington, C; Waight, PA; Walker, WT; Wilkins, S | 1 |
| Abramowicz, D; Brochier, B; Broeders, NE; De Mul, A; Gastaldello, K; Hombrouck, A; Lemy, A; Massart, A; Racapé, J; Thomas, I; Van Gucht, S; Weichselbaum, L; Wissing, KM | 1 |
| Caplanusi, A; Dramé, M; Gillard, P; Knuf, M; Moris, P; Roman, F; Schwarz, TF; Walravens, K | 1 |
| Aavitsland, P; Borgen, K; Feiring, B; Guzmán Herrador, BR; Riise Bergsaker, MA | 1 |
| Deriabin, PG; Galegov, GA; Vasil'ev, AN | 1 |
| Aggarwal, N; Connor, D; Garfield, H; Gupta, A; Langley, JM; Lebel, MH; Li, P; Madan, A; Reich, D; Vaughn, DW | 1 |
| Ikematsu, H; Li, P; Madan, A; Tenjinbaru, K; Vaughn, D | 1 |
| Aboulker, JP; Delfraissy, JF; Desaint, C; Durier, C; Girard, PM; Launay, O; Lévy, Y; Lucht, F; May, T; Michelet, C; Rami, A; Roman, F | 1 |
| Kronborg, G; Nielsen, AB; Nielsen, HS; Nielsen, L; Thybo, S | 1 |
| Chu, L; Frenette, L; Halperin, S; Langley, JM; Li, P; McNeil, S; Vaughn, D | 1 |
| Augustine, G; Bugg, G; Davis, Y; Enstone, J; Hoschler, K; Konje, J; Myles, P; Nguyen-Van-Tam, J; Nicholson, K; Puleston, R; Stephenson, I; Thornton, J; Zambon, M | 1 |
| Braginskiĭ, DM; Krylov, VF; Kulagina, MG; Nagibina, MV; Neĭfakh, EA | 1 |
| Calfee, CS; Choi, J; Fang, X; Gotts, JE; Jones, KD; Leonard, SW; Maishan, M; Matsumoto, S; Matthay, MA; Traber, MG; Wick, KD | 1 |
| Burtseva, EI; Gatich, RZ; Isaeva, EI; Kol'tsov, VD; Kolobukhina, LV; Malinovskaia, VV; Orlova, TG; Vasil'ev, AN; Voronina, FV | 1 |
| Han, SN; Meydani, SN | 2 |
| Abrutyn, E; Bernstein, ED; Gardner, EM; Gross, P; Murasko, DM; Popoff, KA | 1 |
| Braykova, A; Galabov, AS; Mileva, M; Savov, V; Stoeva, E; Tantcheva, L | 1 |
8 review(s) available for d-alpha tocopherol and Influenza, Human
| Article | Year |
|---|---|
Serum antioxidant vitamins and respiratory morbidity and mortality: a pooled analysis.
Topics: Adult; alpha-Tocopherol; Antioxidants; Ascorbic Acid; Bronchitis, Chronic; Emphysema; Humans; Influenza, Human; Morbidity; Nutrition Surveys; Vitamin A; Vitamins | 2022 |
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.
Topics: Adjuvants, Immunologic; Aged; alpha-Tocopherol; Animals; Drug Combinations; Herpes Zoster; Humans; Immunity, Cellular; Immunity, Humoral; Immunogenicity, Vaccine; Influenza, Human; Liposomes; Papillomavirus Infections; Polysorbates; Squalene; Th1 Cells; Th2 Cells; Viral Vaccines | 2018 |
Systems analysis of human vaccine adjuvants.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Animals; Drug Combinations; Glucosides; HIV Infections; Humans; Immunity, Innate; Immunogenicity, Vaccine; Influenza, Human; Lipid A; Liposomes; Malaria, Falciparum; Polysorbates; Squalene; Systems Analysis; Systems Biology; T-Lymphocytes, Helper-Inducer; Toll-Like Receptor 4; Vaccines | 2018 |
An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Antibodies, Viral; Drug Combinations; Female; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Seroconversion; Squalene; Vaccination | 2019 |
Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Antibodies, Viral; Antigens, Viral; Autoimmunity; Canada; Drug Combinations; Europe; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Narcolepsy; Pandemics; Polysorbates; Squalene; Vaccination | 2014 |
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.
Topics: alpha-Tocopherol; Drug Combinations; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Polysorbates; Squalene; Vaccines, Inactivated; Vaccines, Subunit | 2010 |
Vitamin E and infectious diseases in the aged.
Topics: Aged; Aging; Animals; Antioxidants; Dietary Supplements; Humans; Immunity, Innate; Infections; Influenza, Human; Mice; Vitamin E | 1999 |
Antioxidants, cytokines, and influenza infection in aged mice and elderly humans.
Topics: Aged; Aging; Animals; Antioxidants; Cytokines; Humans; Influenza, Human; Mice; Th1 Cells; Th2 Cells; Vitamin E | 2000 |
38 trial(s) available for d-alpha tocopherol and Influenza, Human
| Article | Year |
|---|---|
Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.
Topics: Adjuvants, Immunologic; Adult; alpha-Tocopherol; Animals; Antibodies, Viral; Drug Combinations; Hemagglutination Inhibition Tests; Humans; Immunogenicity, Vaccine; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza Vaccines; Influenza, Human; Polysorbates; Seasons; Squalene; Vaccines, Inactivated | 2022 |
Clinical phase II and III studies of an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66
Topics: Adult; alpha-Tocopherol; Antibodies, Viral; Cell Culture Techniques; Double-Blind Method; Drug Combinations; Female; Humans; Immunogenicity, Vaccine; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Injections, Intramuscular; Male; Middle Aged; Polysorbates; Random Allocation; Squalene; Vaccination; Young Adult | 2020 |
Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial.
Topics: Adjuvants, Immunologic; Adult; alpha-Tocopherol; Antibodies, Viral; Drug Combinations; Female; Hemagglutination Inhibition Tests; Humans; Immunogenicity, Vaccine; Immunologic Memory; Influenza A Virus, H9N2 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Neutralization Tests; Pandemics; Polysorbates; Squalene; Vaccination; Young Adult | 2017 |
AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Human Peripheral Blood Mononuclear Cells.
Topics: Adaptive Immunity; Adjuvants, Immunologic; Adult; alpha-Tocopherol; Double-Blind Method; Drug Combinations; Gene Expression Profiling; Humans; Immunity, Innate; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Leukocytes; Polysorbates; Signal Transduction; Squalene; Young Adult | 2019 |
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; alpha-Tocopherol; Drug Combinations; Female; Follow-Up Studies; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Polysorbates; Seasons; Squalene; Vaccines, Inactivated | 2013 |
Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; alpha-Tocopherol; Antibodies, Viral; B-Lymphocytes; CD4-Positive T-Lymphocytes; Drug Administration Schedule; Drug Combinations; Female; Hemagglutination Inhibition Tests; Humans; Immunity, Cellular; Immunologic Memory; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Polysorbates; Squalene; Vaccination; Young Adult | 2013 |
Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
Topics: Adjuvants, Immunologic; Adolescent; Adult; alpha-Tocopherol; Antibodies, Viral; Antibody Formation; Drug Combinations; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Middle Aged; Polysorbates; Squalene; Vaccination; Young Adult | 2013 |
An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
Topics: Adjuvants, Immunologic; Adolescent; alpha-Tocopherol; Antibodies, Viral; Child; Drug Combinations; Estonia; Female; Hemagglutination Inhibition Tests; Humans; Immunity, Humoral; Immunization Schedule; Immunologic Memory; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Single-Blind Method; Slovakia; Squalene | 2014 |
High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.
Topics: Adult; alpha-Tocopherol; Antibodies, Viral; Antibody Affinity; Drug Combinations; Female; HIV; HIV Infections; HIV Seropositivity; Humans; Immunization, Secondary; Influenza A virus; Influenza Vaccines; Influenza, Human; Male; Mass Vaccination; Middle Aged; Polysorbates; Squalene; Treatment Outcome | 2014 |
AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.
Topics: Adjuvants, Immunologic; Adolescent; alpha-Tocopherol; Antibodies, Viral; Child; Child, Preschool; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Infant; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Placebos; Polysorbates; Single-Blind Method; Squalene; Treatment Outcome; Vaccination; Vaccines, Inactivated | 2015 |
Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study.
Topics: Adjuvants, Immunologic; Age Factors; Aged; Aged, 80 and over; alpha-Tocopherol; Antibodies, Neutralizing; Antibodies, Viral; Belgium; Biomarkers; CD4-Positive T-Lymphocytes; Drug Combinations; Female; Follow-Up Studies; Hemagglutination Inhibition Tests; Humans; Immunity, Cellular; Immunity, Humoral; Immunization Schedule; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Polysorbates; Serologic Tests; Squalene; Time Factors; Treatment Outcome | 2014 |
A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Child, Preschool; Drug Combinations; Female; Fever; Hemagglutination Inhibition Tests; Humans; Incidence; Infant; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Squalene; Vaccines, Inactivated | 2014 |
Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; alpha-Tocopherol; Animals; Antibodies, Neutralizing; Antibodies, Viral; Drug Combinations; Female; Hemagglutination Inhibition Tests; Humans; Immunization, Secondary; Indonesia; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Leukocytes, Mononuclear; Male; Middle Aged; Neutralization Tests; Placebos; Polysorbates; Single-Blind Method; Squalene; Turkey; Young Adult | 2015 |
Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.
Topics: Adjuvants, Immunologic; Adolescent; Adult; alpha-Tocopherol; Antibodies, Viral; Drug Combinations; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Polysorbates; Risk; Squalene; Vaccination; Young Adult | 2014 |
Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Antibodies, Viral; Child; Child, Preschool; Drug Combinations; Female; Follow-Up Studies; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immunity, Cellular; Infant; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Squalene; Vaccination | 2015 |
Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.
Topics: Adjuvants, Immunologic; Adolescent; Adult; alpha-Tocopherol; Animals; Antibodies, Viral; Cell Line; Drug Combinations; Ducks; Embryonic Stem Cells; Female; Humans; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Polysorbates; Single-Blind Method; Squalene; Young Adult | 2015 |
Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
Topics: Adjuvants, Immunologic; Adolescent; Adult; alpha-Tocopherol; Antibodies, Viral; Antibody Formation; Drug Combinations; Female; Hemagglutination Inhibition Tests; Humans; Immunization Schedule; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Pandemics; Polysorbates; Republic of Korea; Squalene; Vaccination; Vaccines, Inactivated; Young Adult | 2015 |
Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains.
Topics: Adjuvants, Immunologic; Adult; alpha-Tocopherol; Antibodies, Viral; Cross Reactions; Drug Combinations; Female; Health Personnel; Hemagglutination Inhibition Tests; Humans; Immunity, Cellular; Immunity, Humoral; Immunization Schedule; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Interferon-gamma; Male; Middle Aged; Polysorbates; Squalene; Time Factors | 2015 |
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.
Topics: Adolescent; alpha-Tocopherol; Antibodies, Neutralizing; Antibodies, Viral; Child; Child, Preschool; Drug Combinations; Female; Hemagglutination Inhibition Tests; Humans; Infant; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Squalene; Treatment Outcome; Vaccination | 2015 |
Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
Topics: Adjuvants, Immunologic; Adolescent; alpha-Tocopherol; Antibodies, Neutralizing; Antibodies, Viral; Child; Child, Preschool; Drug Combinations; Female; Humans; Immunity, Cellular; Infant; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Squalene; Time Factors; Treatment Outcome | 2015 |
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
Topics: Adjuvants, Immunologic; Adult; Age Factors; alpha-Tocopherol; Antibodies, Viral; Double-Blind Method; Drug Combinations; Female; Hemagglutination Inhibition Tests; Hemagglutination, Viral; Humans; Influenza A Virus, H7N9 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Polysorbates; Squalene | 2015 |
A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.
Topics: Adjuvants, Immunologic; Adult; alpha-Tocopherol; Animals; Antibodies, Neutralizing; Antibodies, Viral; Cell Line; Cross Reactions; Drug Combinations; Ducks; Hemagglutination Inhibition Tests; Humans; Immunization Schedule; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Injections, Intramuscular; Male; Orthomyxoviridae Infections; Pandemics; Polysorbates; Squalene; Young Adult | 2015 |
Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant.
Topics: Adjuvants, Immunologic; Adolescent; Adult; alpha-Tocopherol; Antibodies, Viral; Double-Blind Method; Drug Combinations; Female; Humans; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Polysorbates; Squalene; Time Factors; Vaccination; Young Adult | 2016 |
Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.
Topics: Adjuvants, Immunologic; Adolescent; Adult; alpha-Tocopherol; Antibodies, Viral; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Healthy Volunteers; Humans; Immunization Schedule; Influenza A Virus, H7N9 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Placebos; Polysorbates; Single-Blind Method; Squalene; Vaccines, Inactivated; Young Adult | 2016 |
Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
Topics: Aged; Aged, 80 and over; alpha-Tocopherol; Antibodies, Viral; Drug Combinations; Female; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Single-Blind Method; Squalene; Treatment Outcome; Vaccines, Inactivated | 2016 |
Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination.
Topics: Adjuvants, Immunologic; Adult; alpha-Tocopherol; Antibodies, Viral; B-Lymphocytes; Double-Blind Method; Drug Combinations; Humans; Immunization Schedule; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Polysorbates; Squalene; Vaccination | 2016 |
Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.
Topics: Adaptive Immunity; Adjuvants, Immunologic; Adult; alpha-Tocopherol; Animals; Antibodies, Viral; Canada; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Healthy Volunteers; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H7N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Neutralization Tests; Placebos; Polysorbates; Single-Blind Method; Squalene; United States; Vaccines, Inactivated; Young Adult | 2017 |
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
Topics: Adjuvants, Immunologic; Adolescent; alpha-Tocopherol; Child; Child, Preschool; Drug Combinations; Female; Hemagglutination Inhibition Tests; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Squalene; Virion | 2010 |
Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Antibodies, Viral; Antibody Formation; Child, Preschool; Drug Combinations; Female; Hemagglutination Inhibition Tests; Humans; Immunization, Secondary; Infant; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Squalene | 2010 |
Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK childre
Topics: alpha-Tocopherol; Antibodies, Viral; Child; Child, Preschool; Disease Outbreaks; Drug Combinations; Emulsions; Female; Humans; Immunization Programs; Infant; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Program Evaluation; Squalene; United Kingdom | 2010 |
Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents.
Topics: Adjuvants, Immunologic; Adolescent; alpha-Tocopherol; Antibodies, Viral; Child; Drug Combinations; Female; Germany; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Pandemics; Polysorbates; Spain; Squalene; Treatment Outcome; Vaccination | 2011 |
Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Antibodies, Viral; Child; Child, Preschool; Drug Combinations; Female; Hemagglutination Inhibition Tests; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Squalene; Vaccines, Inactivated; Vaccines, Subunit | 2011 |
An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults.
Topics: Adjuvants, Immunologic; Adolescent; Adult; alpha-Tocopherol; Antibodies, Neutralizing; Antibodies, Viral; Female; Hemagglutination Inhibition Tests; Humans; Immunization Schedule; Immunization, Secondary; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Treatment Outcome; Vaccination; Young Adult | 2013 |
Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Child; Child, Preschool; Cohort Studies; Drug Combinations; Female; Hemagglutination Inhibition Tests; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Neutralization Tests; Pandemics; Polysorbates; Squalene; Tocopherols; Vaccination | 2012 |
Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; alpha-Tocopherol; Asian People; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Oils; Squalene | 2012 |
Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Antibodies, Neutralizing; Antibodies, Viral; Antibody Formation; Drug Combinations; Female; France; Hemagglutination Inhibition Tests; Hemagglutinins; HIV Infections; HIV-1; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Prospective Studies; Single-Blind Method; Smoking; Squalene; Time Factors | 2013 |
A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine.
Topics: Adjuvants, Immunologic; Adult; alpha-Tocopherol; Antibodies, Viral; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Squalene; Vaccination; Young Adult | 2012 |
[Viferon suppositories in the treatment of influenza in adults].
Topics: Acute Disease; Adolescent; Adult; Antiviral Agents; Ascorbic Acid; Double-Blind Method; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Ointments; Recombinant Proteins; Suppositories; Vitamin E | 2008 |
27 other study(ies) available for d-alpha tocopherol and Influenza, Human
| Article | Year |
|---|---|
Immunomodulatory Effects of
Topics: Adjuvants, Immunologic; Aged; alpha-Tocopherol; Animals; Humans; Immunity, Humoral; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Interleukin-4; Mice; Mice, Inbred BALB C | 2022 |
Enhanced Influenza Immunity by Nasal Mucosal Administration of the TPGS-Modified Liposomal Vaccine.
Topics: Adjuvants, Immunologic; Administration, Intranasal; alpha-Tocopherol; Animals; Antibodies, Viral; Humans; Immunoglobulin A; Immunoglobulins; Influenza Vaccines; Influenza, Human; Interferon-gamma; Lipids; Liposomes; Mice; Mice, Inbred BALB C; Phosphorylcholine; Polyethylene Glycols; Vitamin E | 2022 |
Formulation Design, Optimization and In Vivo Evaluations of an α-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vaccine.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Animals; Emulsions; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Mice; Mice, Inbred BALB C; Polysorbates; Squalene; Vaccines, Inactivated | 2019 |
Reassessment of the risk of narcolepsy in children in England 8 years after receipt of the AS03-adjuvanted H1N1 pandemic vaccine: A case-coverage study.
Topics: Adolescent; alpha-Tocopherol; Child; Child, Preschool; Drug Combinations; England; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Narcolepsy; Odds Ratio; Pandemics; Polysorbates; Risk Factors; Squalene; Surveys and Questionnaires; Vaccination | 2020 |
Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt.
Topics: Adolescent; Adult; Aged; alpha-Tocopherol; Animals; Drug Combinations; Female; Graft Rejection; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Mice; Middle Aged; Pharmacoepidemiology; Polysorbates; Product Surveillance, Postmarketing; Squalene; Young Adult | 2017 |
Increased humoral immunity by DNA vaccination using an α-tocopherol-based adjuvant.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Animals; Antibodies, Viral; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Humans; Immunity, Cellular; Immunity, Humoral; Immunogenicity, Vaccine; Immunoglobulin G; Influenza Vaccines; Influenza, Human; Mice; Orthomyxoviridae Infections; Vaccination; Vaccines, DNA | 2017 |
Autoimmune diseases and vaccines.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Autoimmune Diseases; Drug Combinations; Guillain-Barre Syndrome; Humans; Influenza Vaccines; Influenza, Human; Meningococcal Infections; Meningococcal Vaccines; Narcolepsy; Papillomavirus Infections; Papillomavirus Vaccines; Polysorbates; Squalene | 2016 |
AS03-adjuvanted influenza vaccine in elderly people.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Drug Combinations; Female; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Male; Polysorbates; Squalene | 2013 |
[Catastrophic consequences of Pandemrix swine flu vaccine containing squalene].
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Drug Combinations; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Narcolepsy; Polysorbates; Squalene | 2013 |
Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; alpha-Tocopherol; Anaphylaxis; Canada; Child; Child, Preschool; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Polysorbates; Quebec; Risk Assessment; Squalene; Young Adult | 2013 |
Vitamin E, vitamin A, and zinc status are not related to serologic response to influenza vaccine in older adults: an observational prospective cohort study.
Topics: Aged; Aged, 80 and over; alpha-Tocopherol; Antibodies, Viral; Deficiency Diseases; Female; Hemagglutination; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Male; Nutritional Status; Prevalence; Prospective Studies; Seasons; Vaccination; Vitamin A; Wisconsin; Zinc | 2014 |
Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients.
Topics: Adjuvants, Immunologic; Adult; Aged; alpha-Tocopherol; Antibodies, Viral; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Immunization Schedule; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Polysorbates; Squalene; Vaccination | 2014 |
Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.
Topics: Adjuvants, Immunologic; Adolescent; Adult; alpha-Tocopherol; Case-Control Studies; Child; Drug Combinations; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Narcolepsy; Polysorbates; Quebec; Retrospective Studies; Squalene; Vaccination; Young Adult | 2014 |
Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.
Topics: Adolescent; Adult; Aged; alpha-Tocopherol; Case-Control Studies; Child; Drug Combinations; Europe; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Paresthesia; Polysorbates; Quebec; Risk Factors; Squalene; Young Adult | 2015 |
Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Antibodies, Viral; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Immunologic; Drug Combinations; Hemagglutination Inhibition Tests; Humans; Immunogenicity, Vaccine; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Polysorbates; Randomized Controlled Trials as Topic; Squalene; Vaccines, Inactivated | 2016 |
Obesity Outweighs Protection Conferred by Adjuvanted Influenza Vaccination.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Alum Compounds; Animals; Antibodies, Neutralizing; Antibodies, Viral; Disease Models, Animal; Drug Combinations; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H7N9 Subtype; Influenza Vaccines; Influenza, Human; Mice, Inbred C57BL; Mice, Obese; Neuraminidase; Obesity; Polysorbates; Respiratory System; Squalene; Survival Analysis; Treatment Outcome; Viral Load; Viral Proteins | 2016 |
An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers.
Topics: Adult; Aged; alpha-Tocopherol; Antibodies, Viral; Drug Combinations; Female; Health Personnel; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Polysorbates; Squalene; Time Factors; Vaccines, Subunit | 2010 |
Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; alpha-Tocopherol; Child; Child, Preschool; Drug Combinations; Emulsions; England; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Polysorbates; Squalene; Young Adult | 2011 |
Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study.
Topics: Adult; Aged; alpha-Tocopherol; Analysis of Variance; Antibodies, Neutralizing; Antibodies, Viral; Belgium; Case-Control Studies; Chi-Square Distribution; Cohort Studies; Drug Combinations; Female; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Humans; Immunosuppressive Agents; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Odds Ratio; Polysorbates; Regression Analysis; Renal Dialysis; Squalene; Time Factors; Treatment Outcome | 2011 |
Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; alpha-Tocopherol; Child; Child, Preschool; Cohort Studies; Drug Combinations; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Norway; Polysorbates; Registries; Retrospective Studies; Squalene; Treatment Outcome; Young Adult | 2012 |
[Antiviral activity of recombinant interferon-alpha-2b in combination with certain antioxidant].
Topics: Acyclovir; alpha-Tocopherol; Animals; Antioxidants; Antiviral Agents; Ascorbic Acid; Cell Line; Chlorocebus aethiops; Drug Synergism; Herpes Simplex; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Interferon alpha-2; Interferon-alpha; Kidney; Lung; Recombinant Proteins; Simplexvirus; Swine; Taurine; Unithiol; Vero Cells | 2011 |
Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults.
Topics: Adult; Aged; Aged, 80 and over; alpha-Tocopherol; Antibodies, Viral; Drug Combinations; Female; HIV Infections; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Polysorbates; Squalene | 2012 |
Multi-centre observational study of transplacental transmission of influenza antibodies following vaccination with AS03(A)-adjuvanted H1N1 2009 vaccine.
Topics: Adult; alpha-Tocopherol; Antibodies, Viral; Drug Combinations; Female; Fetus; Hemagglutination Inhibition Tests; Humans; Immunity, Maternally-Acquired; Infant; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Mass Vaccination; Pandemics; Polysorbates; Pregnancy; Squalene; United Kingdom | 2013 |
[The treatment of pneumonias in influenza using antioxidants].
Topics: Acid-Base Equilibrium; Acute Disease; Adolescent; Adult; alpha-Tocopherol; Antioxidants; Butylated Hydroxytoluene; Humans; Influenza, Human; Lipid Peroxidation; Middle Aged; Pneumonia; Time Factors; Tocopherols; Vitamin E | 1996 |
Aerosolized vitamin E acetate causes oxidative injury in mice and in alveolar macrophages.
Topics: Acetates; Animals; Electronic Nicotine Delivery Systems; Humans; Inflammation; Influenza, Human; Lung Injury; Macrophages, Alveolar; Mice; Oxidative Stress; Vaping; Vitamin E | 2022 |
Immune response to influenza vaccine in healthy elderly: lack of association with plasma beta-carotene, retinol, alpha-tocopherol, or zinc.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antibodies, Viral; beta Carotene; Cell Division; Female; Health Status; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Leukocytes, Mononuclear; Male; Vitamin A; Vitamin E; Zinc | 2000 |
Preventive effect of vitamin E on the processes of free radical lipid peroxidation and monooxygenase enzyme activity in experimental influenza virus infection.
Topics: Animals; Antioxidants; Cytochrome P-450 Enzyme System; Disease Models, Animal; Free Radicals; Humans; Influenza A virus; Influenza, Human; Lipid Peroxidation; Liver; Malondialdehyde; Mice; Mice, Inbred ICR; NADPH-Ferrihemoprotein Reductase; Thiobarbituric Acid Reactive Substances; Vitamin E | 2001 |